Treatment of patients with cisplatin-refractory testicular germ-cell cancer
✍ Scribed by Carsten Bokemeyer; Christian Kollmannsberger; Andreas Harstrick; Jörg Beyer; Arthur Gerl; Jochen Casper; Bernd Metzner; Jörg T. Hartmann; C. Clemm; Hans-Joachim Schmoll; Lothar Kanz
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- French
- Weight
- 78 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
With the use of cisplatin-based combination chemotherapy, metastatic testicular germ-cell tumors can be cured in 70% to 80% of patients. The combination of cisplatin, etoposide and bleomycine (PEB) is considered standard therapy.
📜 SIMILAR VOLUMES
More than half of the patients with testicular germ-cell cancer show impaired spermatogenesis before undergoing cytotoxic treatment. The known pre-treatment infertility and the reversibility of the fertility problems observed in some after successful anti-cancer treatment have so far prevented an as
## Background: Multiinstitutional experience with the management of cerebral metastases from malignant germ cell tumors (mgct) is presented. ## Methods: Clinical data regarding brain metastases from mgct at diagnosis (group 1 [56 patients]) or after cisplatin-based chemotherapy (group 2 [83 patie
Cisplatin, vinblastine and bleomycin (PVB) is very effective therapy in disseminated testicular cancer, but toxicity is severe. A further reduction of vinblastine might reduce the acute toxicity of PVB without compromising the response rate in good-risk patients. Starting in March 1982, 42 consecuti